Huang Ruo hui

Mr. Huang Ruo hui

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2024 in Heliyon
Verified
Journal Article
Open access
ZLZong-Yan Liu
Zong-Yan Liu
HHHuang Ruo hui
Huang Ruo hui
Prostate cancer (PCa) is the most common malignancy of the male urinary system. Mitophagy, as a type of autophagy, can remove damaged mitochondria in cells. Mitophagy-related genes (MRGs) have been shown to play critical roles in the development of PCa. To this end, based on the comprehensive analysis of RNA-seq and scRNA-seq data of PCa samples and their controls, this paper identified PCa subtypes and constructed a prognostic model. In this paper, we downloaded scRNA-seq and RNA-seq data from Gene Expression Omnibus (GEO) and TCGA database. Based on the R package “Seurat” to process the scRNA-seq data, a total of five cell types were identified. Each cell population was scored based on the R package “AUCell” and using the intersection genes between MRGs and each cell population. The B cell population was then identified as a high-scoring cell population. Differentially expressed genes in RNA-seq data were identified based on the R package “limma” and intersected with previously intersected genes. Then, based on univariate Cox regression analysis and Lasso-Cox regression analysis, the prognostic genes were screened, and the risk model was constructed (composed of ADH5, CAT, BCAT2, DCXR, OGT, and FUS). The model is validated on internal and external test sets. Independent prognostic analysis identified age, N stage, and risk score as independent prognostic factors. This paper's risk models and prognostic genes can provide a reference for developing novel therapeutic targets for PCa.

2 November 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
HHHuang Ruo hui
Huang Ruo hui
ZGZi-Lu Ge
Zi-Lu Ge
GXGang Xu
Gang Xu
QZQing-Ming Zeng
Qing-Ming Zeng
WXWei Xia
Wei Xia
BZBIN-BIN Zhang
BIN-BIN Zhang
Clear cell renal cell carcinoma (ccRCC) is the most aggressive and deadly cancer of the urinary system and is regulated by multiple signaling pathways. However, the specific molecular mechanisms underlying ccRCC have not been fully studied or demonstrated. This study aimed to elucidate the function of lysosomal-associated transmembrane protein 5 (LAPTM5) in ccRCC cell lines and animal models and determine the potential underlying mechanisms. Our results demonstrated that LAPTM5 expression in patients with ccRCC was significantly higher in the tumor group than that in the adjacent nontumor group. Moreover, LAPTM5 promoted proliferation, migration, and invasion of ccRCC cells through the gain and loss of the function of LAPTM5 in 786-0 and Caki-1 cell lines. Similar results regarding LAPTM5 overexpression were obtained in BALB/c nude mice. In addition, LAPTM5 activated the Jun N-terminal kinase (JNK)/p38 signaling cascade by interacting with Ras-related C3 botulinum toxin substrate 1 (RAC1). Treatment with an RAC1 inhibitor eliminated the effects of LAPTM5 in ccRCC. In conclusion, these results indicate that LAPTM5 may be a new therapeutic target for ccRCC via activation of the RAC1-JNK/p38 axis.

31 August 2024 in Experimental Cell Research
Verified
Journal Article
Closed access
HHHuang Ruo hui
Huang Ruo hui
QZQing-Ming Zeng
Qing-Ming Zeng
BJBo Jiang
Bo Jiang
GXGang Xu
Gang Xu
GXGuan-Cheng Xiao
Guan-Cheng Xiao
XZXiaofeng Zou Xiaofeng Zou
Xiaofeng Zou Xiaofeng Zou

26 September 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
WXWei Xia
Wei Xia
MYMiao Ye
Miao Ye
BJBo Jiang
Bo Jiang
GXGang Xu
Gang Xu
GXGuancheng Xiao
Guancheng Xiao
HHHuang Ruo hui
Huang Ruo hui
Background: Bone metastasis from prostate cancer severely impacts patient outcomes and quality of life. Anoikis, a form of programmed cell death triggered by the loss of cell-matrix interactions, plays a critical role in cancer progression. However, its precise relationship with prostate cancer-induced bone metastasis remains unclear. This study aims to elucidate this relationship, focusing on anoikis-related gene signatures, molecular pathways, and therapeutic implications.Methods: We used the TCGA-PRAD dataset for training, with MSKCC and GSE70769 as validation cohorts. To evaluate immunotherapy efficacy, we examined IMvigor 210 and GSE91016 datasets, and GSE137829 provided single-cell insights into prostate cancer. Specific anoikis-related genes (ARGs) were identified, and Random Survival Forest analysis and multivariate Cox regression were employed to develop anoikis-linked features. The ‘clustanoikisProfilanoikis’ and ‘GSEA’ packages were used to explore potential ARG-related pathways.Results: Analyzing 553 samples from TCGA, 231 from MSKCC, 94 from GSE70769, and single-cell data from 6 prostate cancer patients (GSE137829), we constructed a prognostic model based on 9 ARGs. GSVA revealed upregulation of carcinogenic pathways, including epithelial-mesenchymal transition, E2F targets, and angiogenesis, with downregulation of metabolic pathways. Significant differences in somatic mutations were observed between cohorts, with a positive correlation between anoikis scores and tumor mutational burden (TMB). Immune landscape analysis suggested high-risk patients might benefit more from chemotherapy than immunotherapy based on their risk score. Single-cell analysis indicated overactivation of carcinogenic pathways in the high anoikis score group.Conclusion: This study elucidates the complex interplay between anoikis and bone metastasis in prostate cancer. Our findings highlight the critical role of anoikis in metastatic progression, enhancing the understanding of key biomarkers and molecular dynamics. The identified anoikis-related gene signatures and disrupted pathways offer promising avenues for predictive and therapeutic strategies in prostate cancer management.

4 June 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
QYQinghui Yin
Qinghui Yin
MLMingsheng Liu
Mingsheng Liu
FXFeng Xie
Feng Xie
HHHuang Ruo hui
Huang Ruo hui

28 October 2025 in BJU International
Verified
Journal Article
Closed access
HHHuang Ruo hui
Huang Ruo hui
LGLiqin Gu
Liqin Gu